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and make the following comments.
We have not stated that the newer quinolones should not be considered for treatment of Gram-positive bone and joint infections. We agree that this group of antibiotics offers an attractive alternative to standard parenteral therapy because of their potency against Gram-positive pathogens and good bioavailability, but caution that the safety of the newer quinolones in long-term use is not yet established. There is a lack of clinical experience and data regarding long-term outcome with these agents treating chronic infections in man, compared with older fluoroquinolones. Quinolone resistance is increasing; the development of resistance to the new fluoroquinolones in Gram-positive organisms has been reported in a pharmacodynamic study, 2 and Frippiat et al.
1 also refer to a clinical case where resistance developed in one of seven of their patients treated for Grampositive prosthetic joint infection. In agreement with Frippiat et al.,
1 our advice to clinicians is that until there are more clinical data available, the addition of a second antibiotic (often rifampicin) should be considered when using a quinolone to treat deep infection, over a prolonged duration.
The optimum dose of rifampicin for use as a second agent in treatment of orthopaedic infection has not been identified, although bone penetration studies have suggested that 600 mg twice daily will give optimal bone concentrations when compared with 300 mg twice daily or 600 mg daily. 3 We usually recommend a dose between 300-600 mg twice daily, depending on the size of the patient and the causal pathogen. This dose is comparable to the dose of 10 -20 mg/kg/day suggested by Frippiat et al. Finally, we agree that whereas linezolid is an attractive option for oral treatment of MRSA and other multi-resistant Gram-positive infection, it is not recommended for use in chronic infection, such as osteomyelitis, due to the lack of safety data when used for >28 days. 4 We have not yet encountered optic neuropathy in association with prolonged linezolid treatment, but have observed thrombocytopenia in some patients, a recognized side effect, 5 and advise clinicians to monitor full blood count weekly when prescribing linezolid for both inpatients and outpatients. Sir, Carbapenems, mainly imipenem and meropenem, are potent agents for the treatment of infections due to multiresistant pseudomonads because these drugs are stable even with extended-spectrum and AmpC lactamases. High-level resistance to carbapenems (MIC >32 mg/L) is still uncommon in Pseudomonas aeruginosa, but can be conferred by metallo-b-lactamases (MBLs).
1 IMP-1 was the first MBL described in P. aeruginosa.
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To date, 17 IMP enzymes and 10 VIM enzymes-a family of MBLs distinct from IMP-have been identified. 3 The bla IMP and bla VIM genes are inserted in integrons, and may be horizontally transferable because some of these integrons are located on conjugative plasmids. Because of its ability to spread, carbapenem resistance related to IMP-and VIM-MBL production has become a serious concern.
During 2001 -2002, 24 isolates of P. aeruginosa resistant to imipenem were obtained at Wuxi No.1 Hospital affiliated with Nanjing Medical University in China. Antimicrobial susceptibility tests for MBL-producing Gram-negative bacilli were performed by the microdilution method with cation-adjusted Mueller-Hinton broth (Oxoid, Basingstoke, UK) according to the recommendations of the NCCLS. A disc-diffusion test, with 2-mercaptopropionic acid as an MBL inhibitor, was used to screen for MBL producers, as described by Arakawa et al. Seven of 24 isolates of P. aeruginosa resistant to imipenem showed potentiation of ceftazidime by 2-mercaptopropionic acid, suggesting the production of MBL. Characteristics of these isolates are listed in Table 1 . All seven were resistant to imipenem, piperacillin, cefotaxime, cefazolin, cefalothin, cefoxitin and ceftazidime. Their susceptibilities to aztreonam and ciprofloxacin varied.
All seven isolates positive by the screening test gave PCR amplicons using primers specific for bla IMP alleles; the remaining 17 isolates were negative. None of the 24 isolates contained bla VIM alleles. The PFGE patterns of the IMP-producing isolates were identical, suggesting nosocomial spread of the strain. Sequence analysis revealed that the bla IMP allele of this strain differed from bla IMP-1 (GenBank AY168635) by replacements of T ! C, T ! C and C ! T at nucleotides 87, 171 and 394 of the structural gene, respectively. These mutations were all silent, so the strain produced IMP-1 enzyme. This is the first report of IMP-1 MBL in China. The carbapenem-resistant phenotype of the 17 P. aeruginosa that lacked bla IMP and bla VIM genes probably resulted from the loss of the outer membrane protein OprD, or up-regulation of the MexAB-OprM efflux pump.
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